Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy
{"title":"参与减肥试验的肥胖或超重稳定双相情感障碍患者暴食障碍的特征-事后分析。","authors":"Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy","doi":"10.1080/13651501.2025.2549307","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.</p><p><strong>Methods: </strong>This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.</p><p><strong>Results: </strong>Compared to those without BED (<i>N</i> = 43), participants with BED (<i>N</i> = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (<i>N</i> = 9) and placebo (<i>n</i> = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (<i>p</i> = .04), constipation (<i>p</i> = .02) and anxiety (<i>p</i> = .02).</p><p><strong>Conclusions: </strong>RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.</p>","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-4"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.\",\"authors\":\"Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy\",\"doi\":\"10.1080/13651501.2025.2549307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.</p><p><strong>Methods: </strong>This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.</p><p><strong>Results: </strong>Compared to those without BED (<i>N</i> = 43), participants with BED (<i>N</i> = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (<i>N</i> = 9) and placebo (<i>n</i> = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (<i>p</i> = .04), constipation (<i>p</i> = .02) and anxiety (<i>p</i> = .02).</p><p><strong>Conclusions: </strong>RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.</p>\",\"PeriodicalId\":14351,\"journal\":{\"name\":\"International Journal of Psychiatry in Clinical Practice\",\"volume\":\" \",\"pages\":\"1-4\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry in Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13651501.2025.2549307\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2025.2549307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.
Objective: To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.
Methods: This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.
Results: Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).
Conclusions: RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.
期刊介绍：
International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry.
The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice.
Focus on the practical aspects of managing and treating patients.
Essential reading for the busy psychiatrist, trainee and interested physician.
Includes original research papers, comprehensive review articles and short communications.
Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
